非小细胞肺癌软脑膜转移的演变格局:国际多中心当代队列研究
该国际多中心回顾性研究纳入2007至2024年八家机构的2052例晚期NSCLC软脑膜转移患者,按分子亚型分析。结果显示LMD累积患病率在EGFR、ALK、ROS1、ERBB2等驱动基因亚型中较高,当代队列LMOS较历史队列改善(11.5 vs 7.3个月,P<0.0001),TKI和ICI分别在有驱动基因和非AGA患者中带来生存获益。
要点
- EGFR、ALK、ROS1、ERBB2等驱动基因亚型LMD累积患病率高于非AGA患者。
- 当代队列LMOS较历史队列显著改善(11.5 vs 7.3个月,P<0.0001)。
- EGFR突变患者LMD后继续使用CNS穿透性TKI与更长LMOS相关(12.4 vs 6.0个月)。
核心结论
- LMD患病率上升,主要因晚期NSCLC生存期延长所致。
- 当代系统治疗(TKI和ICI)是延迟LMD发生和改善LMD生存的主要贡献因素。
研究设计与样本
- 国际多中心回顾性研究,纳入亚洲、美国、欧洲八家机构2007至2024年诊断的晚期NSCLC合并LMD患者2052例。
- 按分子亚型分析:EGFR(n=1610)、ALK(n=141)、其他可靶向基因组变异(other AGA,n=137)、非AGA(n=164)。
- 主要终点为自LMD诊断起的总生存期(LMOS)。
主要发现
- LMD累积患病率:EGFR 11.1%、ALK 11.2%、ROS1 16%、ERBB2 12.3%、非AGA 3.6%。
- 全体患者中位LMOS为10.9个月(95%CI 10.0-11.8个月)。
- 当代队列较历史队列LMOS改善(7.3 vs 11.5个月,P<0.0001),各分子亚型均一致。
- AGA患者中TKI与LMOS改善相关(HR 0.39,95%CI 0.31-0.48,P<0.0001)。
- 非AGA患者中ICI带来生存获益(HR 0.45,95%CI 0.25-0.84,P=0.012)。
关键数值与推荐
- 按EANO-ESMO诊断标准,I型(脑脊液细胞学阳性)LMOS显著短于II型(MRI和/或症状阳性)。
- EGFR突变队列中,CNS穿透性TKI使用延迟LMD发生(P<0.0001)。
- EGFR突变队列中,LMD诊断后继续CNS穿透性TKI与更长LMOS相关(12.4 vs 6.0个月,P<0.0001)。
临床怎么用
- 对驱动基因阳性NSCLC患者应关注LMD风险,尤其EGFR、ALK、ROS1、ERBB2亚型。
- AGA患者LMD后使用TKI可改善生存,EGFR突变者优先选择CNS穿透性TKI并考虑持续使用。
- 非AGA患者LMD后ICI治疗与生存获益相关。
局限性
- 回顾性研究设计,存在选择偏倚和信息偏倚可能。
- 各分子亚型样本量不均衡,非AGA和少见变异亚组样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Leptomeningeal metastatic disease (LMD) represents a devastating complication of non-small-cell lung cancer (NSCLC) with a poor prognosis. Our understanding of LMD is limited in the era of molecular testing and emerging therapeutic options for lung cancer. PATIENTS AND METHODS: We conducted an international, multicenter, retrospective study involving eight institutions across Asia, United States, and Europe. Patients diagnosed with LMD from advanced NSCLC were identified (2007-2024). Clinicopathological characteristics, treatment patterns, and outcomes were analyzed. The primary endpoint was overall survival from the LMD diagnosis (LMOS). RESULTS: A total of 2052 patients with NSCLC and LMD were included and analyzed by molecular subtypes: epidermal growth factor receptor (EGFR) (n = 1610), ALK (n = 141), other actionable genomic alterations (other AGA; n = 137), and non-AGA (n = 164). The cumulative prevalence of LMD by molecular subgroups was EGFR, 11.1%; ALK, 11.2%; ROS1, 16%; ERBB2, 12.3%, non-AGA, 3.6%. A higher proportion of LMD was diagnosed >3 years after initial metastatic diagnosis. By the European Association of Neuro-Oncology (EANO)-European Society for Medical Oncology (ESMO) diagnostic criteria, type I (cerebrospinal fluid cytology positive) had significantly shorter LMOS than type II (magnetic resonance imaging and/or symptom positive). Median LMOS was 10.9 months [95% confidence interval (CI) 10.0-11.8 months] in all patients. Compared with historical cohorts, patients demonstrated improved LMOS in contemporary cohorts (7.3 versus 11.5 months, P < 0.0001), across all molecular subtypes. In AGA NSCLC, tyrosine kinase inhibitors (TKIs) were associated with improved LMOS [hazard ratio (HR) 0.39, 95% CI 0.31-0.48, P < 0.0001]. Immune checkpoint inhibitors (ICIs) conferred survival benefit in non-AGA patients (HR 0.45, 95% CI 0.25-0.84, P = 0.012). For the EGFR-mutated cohort, central nervous system (CNS)-penetrant TKI usage delayed LMD onset (P < 0.0001). Continued CNS-penetrant TKIs after LMD diagnosis were associated with longer LMOS (12.4 versus 6.0 months, P < 0.0001). CONCLUSIONS: The prevalence of LMD is rising, largely due to prolonged survival in advanced NSCLC. Contemporary systemic treatments, including TKIs and ICIs, were the main contributors to delayed LMD onset and improved LMD survival.
引用
- Zheng MM, Xia Y, Pan K, et al. The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study. Ann Oncol. 2025. PMID: 41125209. doi:10.1016/j.annonc.2025.09.140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。